342 related articles for article (PubMed ID: 33860927)
1. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
[TBL] [Abstract][Full Text] [Related]
6. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
9. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
Barrett A; Boye KS; García-Pérez LE; Giorgino F; Guerci B; Füchtenbusch M; Yu M; Sapin H; Dib A; Heitmann E; Federici MO; Lebrec J
J Med Econ; 2024; 27(1):866-879. PubMed ID: 38963346
[TBL] [Abstract][Full Text] [Related]
10. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
11. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
13. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
Saunders WB; Nguyen H; Kalsekar I
Diabetes Metab Syndr Obes; 2016; 9():217-23. PubMed ID: 27486339
[TBL] [Abstract][Full Text] [Related]
14. Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.
Svensson AM; Toll A; Lebrec J; Miftaraj M; Franzén S; Eliasson B
Diabetes Obes Metab; 2021 Mar; 23(3):720-729. PubMed ID: 33289287
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
16. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
18. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S
Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
[TBL] [Abstract][Full Text] [Related]
19. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
Metabolism; 2020 May; 106():154190. PubMed ID: 32109448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
